Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 10Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pulmonary Neuroendocrine Tumor 1Neuroendocrine Tumor Grade 3 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Quality of Life 2tislelizumab 1surufatinib 1regorafenib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1copper dotatate CU-64 1Surveys and Questionnaires 1Poly(ADP-ribose) Polymerase Inhibitors 1Patient Reported Outcome Measures 1PM 01183 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Irinotecan 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Cyclophosphamide 1Cryotherapy 1Control Groups 1Clinical Trials, Phase II as Topic 1Biological Therapy 1Betaine 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × surufatinib × NET × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡